NTRA vs. TMO: Natera vs. Thermo Fisher Scientific Stock Comparison
How do Natera (NTRA) and Thermo Fisher Scientific (TMO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Natera (NTRA) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NTRA is classified in Biotechnology while TMO is classified in Life Sciences Tools & Services.
| Profile Item | NTRA | TMO |
|---|---|---|
| Name | Natera, Inc. | Thermo Fisher Scientific Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 45.05 billion USD | 257.42 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | July 1, 2015 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | NTRA | TMO |
|---|---|---|
| Total Return (1Y) | 61.03% | 24.62% |
| Total Return (3Y, Annualized) | 92.02% | 17.34% |
| Total Return (5Y, Annualized) | 23.20% | 3.11% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | NTRA | TMO |
|---|---|---|
| Volatility (1Y, Annualized) | 52.30% | 29.96% |
| Beta (5Y) | 1.58 | 0.83 |
| Max Drawdown (5Y) | -75.72% | -40.95% |
| Avg. Volume (3M) | 1.68M | 2.10M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | NTRA | TMO |
|---|---|---|
| Sharpe Ratio (1Y) | 1.09 | 0.68 |
| Sortino Ratio (1Y) | 1.63 | 1.02 |
Profitability
ROE (TTM)
Natera (NTRA) reports a negative ROE of -10.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Thermo Fisher Scientific (TMO) reports 13.38%, ranking against industry peers normally.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-10.55%
- Max
- 109.18%
- Q3
- 6.23%
- NTRA
- -10.55%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.38%
- Max
- 109.18%
- TMO
- 13.38%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Natera (NTRA) reports a negative net margin of -5.66%, usually indicating a net loss over the period. Meanwhile Thermo Fisher Scientific (TMO) reports 14.94%, ranking against industry peers normally.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.66%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- NTRA
- -5.66%
- Min
- -17.05%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.94%
- Max
- 18.05%
- TMO
- 14.94%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Natera (NTRA) reports a negative operating margin of -7.64%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Thermo Fisher Scientific (TMO) reports 20.19%, ranking against industry peers normally.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-7.64%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- NTRA
- -7.64%
- Q1
- -78.82%
- Min
- -207.40%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.19%
- Max
- 83.12%
- TMO
- 20.19%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | NTRA | TMO |
|---|---|---|
| ROE (TTM) | -10.55% | 13.38% |
| ROA (TTM) | -6.79% | 5.19% |
| Net Margin (TTM) | -5.66% | 14.94% |
| Operating Margin (TTM) | -7.64% | 20.19% |
| Gross Margin (TTM) | 65.14% | 41.26% |
Growth
Revenue Growth
Both Natera (NTRA) at 35.90% and Thermo Fisher Scientific (TMO) at 3.91% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Thermo Fisher Scientific (TMO) reports EPS growth of 7.32%, ranked against its industry; Natera (NTRA) has no EPS growth figure this period.
Growth Metrics
| Metric | NTRA | TMO |
|---|---|---|
| Revenue Growth (YoY) | 35.90% | 3.91% |
| Revenue Growth (3Y CAGR) | 41.14% | -0.27% |
| EPS Growth (YoY) | -- | 7.32% |
| EPS Growth (3Y CAGR) | -- | 0.21% |
Financial Strength
Current Ratio (MRQ)
Natera (NTRA) at 2.81 keeps current ratio within its industry’s typical mid-range, while Thermo Fisher Scientific (TMO) at 1.81 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TMO.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.81
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- NTRA
- 2.81
- Q1
- 2.47
- Min
- 0.10
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.81
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TMO
- 1.81
- Min
- 0.10
Debt / Equity (MRQ)
Natera (NTRA) at 0.13 carries an industry-typical debt-to-equity mix, while Thermo Fisher Scientific (TMO) at 0.75 uses more debt funding than most peers.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NTRA
- 0.13
- Q1
- 0.02
- Min
- 0.00
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.75
- Max
- 1.42
- TMO
- 0.75
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | NTRA | TMO |
|---|---|---|
| Current Ratio (MRQ) | 2.81 | 1.81 |
| Debt / Equity (MRQ) | 0.13 | 0.75 |
| Net Debt / EBITDA | -- | 2.91 |
Dividends
Dividend Yield (TTM)
Natera (NTRA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a yield of 0.27%, ranking against industry peers normally.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.27%
- TMO
- 0.27%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Natera (NTRA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a payout of 9.70%, ranking against industry peers normally.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.70%
- TMO
- 9.70%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | NTRA | TMO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.27% |
| Dividend Payout Ratio (TTM) | 0.00% | 9.70% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Thermo Fisher Scientific (TMO) trades at 36.64 times trailing earnings, ranked against its peers, while Natera (NTRA) has no P/E ratio this period.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- NTRA
- --
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.64
- Max
- 85.34
- Q3
- 43.46
- TMO
- 36.64
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Natera (NTRA) at 15.49 and Thermo Fisher Scientific (TMO) at 5.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.49
- Max
- 58.18
- Q3
- 25.77
- NTRA
- 15.49
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.44
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- TMO
- 5.44
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Thermo Fisher Scientific (TMO) at 4.70 sits near its industry’s typical P/B ratio, while Natera (NTRA) at 23.99 prices above its benchmark range — NTRA looks rich relative to book.
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.99
- NTRA
- 23.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
TMO
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- TMO
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | NTRA | TMO |
|---|---|---|
| P/E Ratio (TTM) | -- | 36.64 |
| P/S Ratio (TTM) | 15.49 | 5.44 |
| P/B Ratio (MRQ) | 23.99 | 4.70 |
| Free Cash Flow Yield (TTM) | 0.19% | 2.50% |